• Regenerex flagged substantial additional accounting, reconciliation, financial reporting, and review work tied to its delayed 2025 Form 10-K filing.
• Quarterly reports for the periods ended March 31, 2026 and June 30, 2026 remain unfiled, leaving those quarterly financials incomplete.
• No Form 12b-25 late-filing notices were submitted for the delinquent 10-Qs.
• Management is working with finance staff and advisors to complete the filings, strengthen reporting processes, and return to timely SEC compliance.
• The company does not expect the reporting delays to change operations, business strategy, or ongoing business activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenerex Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001472375-26-000214), on September 01, 2026, and is solely responsible for the information contained therein.